Opportunity ID: 326175

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-20-PRMRP-TTDA-COV
Funding Opportunity Title: CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 4
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 08, 2020
Last Updated Date: Apr 08, 2020
Original Closing Date for Applications: Jun 12, 2020
Current Closing Date for Applications: Jun 12, 2020
Archive Date: Jul 12, 2020
Estimated Total Program Funding: $25,000,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The PRMRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas published in this funding opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.

The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. (A “Knowledge Product” is a non-materiel product that addresses an identified need in a Topic Area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.) The Principal Investigator (PI) must provide a transition plan (including potential funding and resources, see Attachment 8) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the PRMRP award. PIs are encouraged to develop relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development.

Proof of concept demonstrating the potential utility of the proposed product, or a prototype/ preliminary version of the proposed product, should already be established. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 326175 Full Announcement-FY20 PRMRP TTDA COV -> PRMRP_FY20_TTDA_COV_PA_GG.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00260868 Apr 08, 2020 Jun 12, 2020 View

Package 1

Mandatory forms

326175 RR_SF424_2_0-2.0.pdf

326175 AttachmentForm_1_2-1.2.pdf

326175 RR_PersonalData_1_2-1.2.pdf

326175 RR_KeyPersonExpanded_2_0-2.0.pdf

326175 RR_Budget_1_4-1.4.pdf

326175 PerformanceSite_2_0-2.0.pdf

Optional forms

326175 RR_SubawardBudget30_1_4-1.4.pdf

2025-07-09T16:38:19-05:00

Share This Post, Choose Your Platform!

About the Author: